

POSTERS (3)

	<i>Attended</i>
<u>Oral Posters P001-P020</u> <u>Bone Formation, Cartilage, and Bone Matrix P021- P135</u> <u>Bone Resorption and its Regulation P136-P182</u>	Thursday 13:00-14:00
<u>Cancer and Metabolic Bone Diseases other than Osteoporosis P183-P237</u> <u>Osteoporosis: Pathophysiology, Genetics and Epidemiology P238-P337</u>	Friday 13:00-14:00
<u>Osteoporosis: Assessment and Treatment P338 -P490</u>	Saturday 13:00-14:00

OSTEOPOROSIS: ASSESSMENT AND TREATMENT

These posters will be attended on Saturday, 13 May 2006, 13:00 – 14:00

P338 DIAGNOSTIC PERFORMANCE OF RISK FACTORS IN PATIENTS REFERRED FOR OSTEODENSITOMETRY

M. Malling¹, P. C. Eskildsen¹, B. Abrahamsen*¹

¹RASK Osteoporosis Clinic, Roskilde University Hospital, Koge, Denmark

P339 THREE-FOURTHS OF FRAGILITY FRACTURES ARE NONVERTEBRAL AMONG WOMEN IN MANAGED CARE

J. D. Adachi*¹, S. Magowan², J. Lange³, S. Gehlbach⁴

¹Saint Joseph's Hospital, McMaster University, Hamilton, Canada, ²Medical and Technical Affairs,

³Epidemiology and PharmacoEconomics, Procter and Gamble Pharmaceuticals, Mason,

⁴Epidemiology, University of Massachusetts, Amherst, United States

P340 GREATER THAN 90% OF MANAGED CARE COSTS FOR FRAGILITY FRACTURES ARE NONVERTEBRAL IN NATURE AMONG WOMEN

J. Adachi*¹, S. Magowan², N. Borisov³, J. Lange⁴, R. Ohsfeldt⁵

¹St. Joseph's Hospital, McMaster University, Hamilton, Canada, ²Medical and Technical Affairs,

³Epidemiology and PharmacoEconomics, ⁴Epidemiology, Procter and Gamble Pharmaceuticals,

Mason, ⁵School of Rural Public Health, Texas AM, Bryan, United States

P341 RENAL TOLERABILITY PROFILE OF INTERMITTENT INTRAVENOUS IBANDRONATE INJECTIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: DIVA 2-YEAR ANALYSIS

S. Adami*¹, C. Benhamou², V. Vyskocil³, C. Leigh⁴, F. Sedarati⁴, B. Minic⁴, D. M. Reid⁵

¹., University of Verona, Verona, Italy, ²., IPROS-CHR, Orleans, France, ³., University Hospital, Plzen,

Czech Republic, ⁴., F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵., University of Aberdeen,

Aberdeen, United Kingdom

P342 AUTOMATIC ASSESSMENT OF VERTEBRAL SHAPE USING ACTIVE APPEARANCE MODELS

J. E. Adams*¹, M. G. Roberts¹, T. Cootes¹

¹Imaging Science and Biomedical Engineering, University of Manchester, Manchester, United Kingdom

P343 STRONTIUM RANELATE PREVENTS ALTERATION OF BONE STRENGTH IN OVX RATS BY IMPROVING INTRINSIC BONE TISSUE QUALITY

P. Ammann*¹, I. Badoud¹, V. Shen², S. Bain², I. Dupin-Roger³, R. Rizzoli¹

¹Division of Bone Diseases, Department of Rehabilitation and Geriatrics, University Hospital, Geneva,

Switzerland, ²SkeleTech, MDS Pharma Services, Bothell, United States, ³Rheumatology Division,

Groupe Servier, Courbevoie, France

P344 4 YEARS CONTINUOUS TREATMENT WITH RISEDRONATE AND ITS EFFECT ON BONE TURNOVER MARKERS AND QUALITY OF LIFE OF POSTMENOPAUSAL WOMWEN

L. Anadiotis¹, I. C. H. Koulouris*², G. Skarantavos³, G. C. H. Koulouris⁴

¹Biochemistry, Evangelismos General Hospital, ²Orthopaedics, 1st IKA Egaleo, ³Reumatology, Attikon University Hospital, ⁴Psychiatry, Aeginition University Hospital, Athens, Greece

P345 EFFECT ON BONE DENSITY OF ONE YEAR TREATMENT OF OSTEOPOROTIC PATIENTS WITH TERIPARATIDE VERSUS RISENDRONATE

A. Anastasilakis*¹, S. Polyzos¹, Z. Efstathiadou¹, G. Koukoulis², M. Kita¹, A. Avramidis¹

¹Department of Endocrinology, Hippocraton General Hospital, Thessaloniki, ²Department of Endocrinology, Medical School of Thessalia, Larisa, Greece

P346 PREVENTION OF THE BONE TISSUE QUALITATIVE DETERIORATION IN MENOPAUSE WITH RALOXIFENE

P. Astazi*¹, L. Mirone²

¹Internal Medicine, OsteoRESEARCH, ²Reumatology, Catholic University School of Medicine, ROMA, Italy

P347 CROSS-CALIBRATION OF THE LEXXOS CONE BEAM DENSITOMETER WITH THE HOLOGIC QDR-4500

M. Audran*¹, Y. Simon¹, R. Levasseur¹, D. Chappard¹, E. Legrand¹

¹INSERM, EMI 0335, Faculty of medicine, Angers, France

P348 A NEW DIGITAL MORPHOMETRIC METHOD TO ASSESS VERTEBRAL FRACTURES IN CLINICAL PRACTICE: A MULTICENTER PILOT STUDY

D. Banzer*¹, R. Andresen², G. Möller³

¹Radiology, Heerstr. 75, D-14055 Berlin, ²Radiology, KMG Klinikum Güstrow GmbH, D-18273 Güstrow, ³Medical Affairs, Procter and Gamble Pharmaceuticals - Germany GmbH, D-65824 Schwalbach am Taunus, Germany

P349 TERIPARATIDE, HRT AND OSTEOPOROSIS

A. Bazarra-Fernandez*¹

¹Ob Gyn., Juan Canalejo University Hospital, La Coruña, Spain

P350 PATIENT PREFERENCE FOR ONCE-MONTHLY ORAL IBANDRONATE AND WEEKLY ORAL ALENDRONATE IN POSTMENOPAUSAL OSTEOPOROSIS: THE BALTO II STUDY

C. Benhamou*¹, A. A. Licata², V. Devas³, D. Masanauskaitė⁴, P. Hadji⁵

¹Porte Madeleine Hospital, Orleans, France, ²Cleveland Clinical Foundation, Cleveland,

³GlaxoSmithKline, Colleagueville, United States, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland,

⁵University of Marburg, Marburg, Germany

P351 IMPACT OF PRIOR BISPHOSPHONATE THERAPY ON THE ANABOLIC EFFECTS OF TERIPARATIDE: RATIONALE AND DESIGN OF THE OPTAMISE STUDY

J. P. Bilezikian*¹, N. B. Watts², P. D. Delmas³, P. Miller⁴

¹Professor, Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY, ²Professor of Medicine, Director, Osteoporosis and Bone Health Program, University of Cincinnati College of Medicine, Cincinnati, OH, United States, ³Professor, Medicine and

Rheumatology, Director, Inserm Research Unit, Inserm Research Unit 403 and Claude Bernard University of Lyon, Lyon, France, ⁴Medical Director, Colorado Center for Bone Research, Lakewood,

CO, United States

P352 WHAT IS HIGH BONE TURNOVER ?

J. A. Blázquez*¹, L. Navarro², F. Mateos¹, M. Cháfer², E. Almar³, J. Del Pino⁴

¹Internal Medicine, ²Clinical Chemistry, University Hospital, ³Epidemiology, Health Department, Albacete, ⁴Rheumatology, University Hospital, Salamanca, Spain

P353 MUSCULOSKELETAL ADVERSE EFFECTS OF ORAL TREATMENT WITH ONCE WEEKLY ALENDRONATE AND RISEDRONATE IN PATIENTS WITH OSTEOPOROSIS
O. Bock*¹, H. Börst¹, M. Stephan-Oelkers¹, C. Degner¹, D. Felsenberg¹

¹Centre for Muscle and Bone Research, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

P354 RISEDRONATE TREATMENT PRODUCES A SIGNIFICANT REDUCTION IN THE RISK OF CLINICAL VERTEBRAL FRACTURES OVER 3 YEARS

S. Boonen*¹, S. Magowan², I. Barton², J. Adachi³

¹Metabolic Bone Diseases, Leuven University Center for Metabolic Bone Diseases, Leuven, Belgium,

²Medical and Technical Affairs, Procter and Gamble Pharmaceuticals, Mason, United States, ³St Joseph's Hospital, McMaster University, Hamilton, Canada

P355 CLINICAL & BIOLOGICAL SAFETY OF LONG TERM USE OF CALCIUM AND VITAMIN D SUPPLEMENTATION IN ELDERLY WOMEN WITH VITAMIN D INSUFFICIENCY

M. Brazier*¹, S. Kamel¹, F. Grados¹, M. Mathieu², P. Fardellone¹

¹Departments of Biochemistry and Rheumatology, University Hospital Center, Amiens, ²Medical Affairs, Laboratoires Innothera, Arcueil, France

P356 STRONTIUM RANELATE EFFECT ON PROLIFERATION AND OPG EXPRESSION IN OSTEOBLASTS

T. Brennan*¹, M. S. Rybchyn¹, A. D. Conigrave², R. S. Mason¹

¹School of Medical Sciences and Institute for Biomedical Research, ²School of Molecular and Microbial Biosciences, University of Sydney, Sydney, Australia

P357 THE EFFECTS OF STRONTIUM ON BONE ULTRASTRUCTURE: INSIGHTS FROM LABORATORY SCANNING SMALL ANGLE X-RAY SCATTERING (SSAXS)

M. H. Bünger*¹, T. P. K. Hansen¹, F. Besenbacher¹, B. L. Langdahl², H. Oxlund³, J. S. Pedersen⁴, H. Birkedal⁴

¹Interdisciplinary Nanoscience Center, University of Aarhus, ²Department of Endocrinology and Metabolism C, Aarhus Sygehus, ³Department of Anatomy, ⁴Department of Chemistry, University of Aarhus, Aarhus, Denmark

P358 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR PREVENTS DISORDERS OF BONE REMODELING INDUCED BY LOW-DOSE METHOTREXATE IN RATS

U. Cegiela¹, **W. Janiec***¹

¹Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

P359 ANALGESIC ACTIVITY OF DIFFERENT ANTI-OSTEOPOROTIC DRUGS

R. Y. Chechurin*¹

¹Internal Medicine, B&C, Moscow, Russian Federation

P360 TREATMENT RESULTS FOR POSTMENOPAUSAL OSTEOPOROSIS IN MOSCOW OUT-PATIENTS

R. Y. Chechurin*¹, M. P. Rubin²

¹Internal Medicine, BC-med, ²Diagnostics, City Clinical Hospital 23, Moscow, Russian Federation

P361 POBLATIONAL SCREENING WITH ACCUDEXA AND FRACTURE INDEX. RELATIONSHIP WITH HIP FRACTURE INCIDENCE

M. Círia*¹, M. Coll², I. Gonzalez³, J. Fernandez⁴, L. Perez-Edo¹, J. Blanch¹, X. Nogués⁵, P. Benito¹

¹Rheumatology, Institut Municipal d'Assistència Sanitària, ²Rheumatology, Hospital de Mataró,

³Primary Care Unit, CAP Maragall, ⁴Primary Care Unit, CAP Besós, ⁵Internal Medicine, Institut Municipal d'Assistència Sanitària, Barcelona, Spain

P362 EVALUATION OF THE PERFORMANCE OF NEW PEDIATRIC LEAN MASS ASSESSMENT ON THE LUNAR PRODIGY

V. Cirmanova*¹, I. Zofkova¹, M. Hill¹, M. Bayer², P. Kasalicky³, J. Rosa³

¹Department of Clinical Endocrinology, Institution of Endocrinology, ²Department of Paediatrics, 1st Medical Faculty, ³Bone Metabolic Unit, DC Mediscan, Prague, Czech Republic

P363 CROSS CALIBRATION OF GE-LUNAR IDXA AND PRODIGY BONE DENSITOMETERS

L. Cole*¹, E. Mossman¹, M. McClung¹

¹Central DXA Laboratory, Oregon Osteoporosis Center, Portland, United States

P364 VERTEBRAL FRACTURE ASSESSMENT WITH DXA

F. Colson*¹, M. Ollagnon²

¹Service de rhumatologie du Pr Vignon, Centre hospitalier Lyon-sud, Lyon, ²Centre, D'absorptiométrie osseuse, Villeurbanne, France

P365 RATIONALE AND DESIGN OF THE PERSIST STUDY (PERSISTENCE STUDY OF IBANDRONATE VERSUS ALENDRONATE).

A. L. Cooper on behalf of the PERSIST Study Investigators*¹

¹Bridge Medical Centre, Crawley, United Kingdom

P366 TERIPARATIDE MAY SUBSTITUTE OR BE ADIUVANT TO VERTEBROPLASTY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROTIC VERTEBRAL FRACTURES: A REPORT OF TWO CASES

C. Corradini*¹, F. F. M. Ulivieri², M. Macchia¹, C. C. A. Verdoia¹

¹Orthopaedic and Traumatologic Clinic, University of Milan, ²Nuclear Medicine, IRCSS Policlinico, Milan, Italy

P367 TERIPARATIDE TREATMENT REDUCES VERTEBRAL HEIGHT LOSS IN PATIENTS WITH SEVERE PREVALENT VERTEBRAL FRACTURES

G. G. Crans*¹, H. K. Genant², S. Prevrhal², E. V. Glass¹, J. H. Krege¹

¹Eli Lilly and Company, Indianapolis, ²UCSF-OARG and Synarc Inc., San Francisco, United States

P368 HIGH RESOLUTION PQCT OF THE RADIUS AND TIBIA

N. Dalzell*¹, S. K. Kaptoge¹, B. Koller², P. Ruegsegger², A. Berthier³, L. Braak³, J. Reeve¹

¹Medicine, University of Cambridge, Cambridge, United Kingdom, ²Scanco, Zurich, Switzerland, ³MEDES, Toulouse, France

P369 MECHANICAL STIMULI ALTER ADIPOCYTE TO OSTEOBLAST DIFFERENTIATION OF BONE MARROW STROMAL CELLS THROUGH PPARGAMMA

V. David*¹, A. Martin¹, L. Malaval¹, A. Guignandon¹, M. Lafage-Proust¹, L. Vico¹

¹LBTO INSERM366, Faculté de médecine, Saint-Etienne, France

P370 IN VITRO LONG-TERM CULTURE OF CANCELLOUS BONE EXPLANTS UNDER PHYSIOLOGICAL STRAIN REGIMEN

V. David*¹, A. Martin¹, L. Malaval¹, M. Lafage-Proust¹, A. Guignandon¹, D. B. Jones², L. Vico¹

¹LBTO INSERM366, Faculté de médecine, Saint-Etienne, France, ²Experimental Orthopaedics and Biomechanics, Philipps University, Marburg, Germany

P371 BONE RESORPTION IN STROKE AND INSTITUTIONALISED SUBJECTS

M. W. Davie*¹, N. J. Bainbridge¹, M. J. Haddaway¹

¹Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom

P372 FEMUR BONE MASS DISTRIBUTION BY DXA PREDICTS HIP FRACTURE RISK BETTER THAN FEMUR BONE DENSITY

L. Del Rio*¹, S. Di Gregorio¹, A. Bagur², J. Rosales¹, R. Vila¹, J. Pascual¹, M. Garcia¹, C. Sole¹, E. Bonell¹, D. Bambalere¹

¹Cetir, Centre Medic, Barcelona, Spain, ²Hospital, De Clinicas, Buenos Aires, Argentina

P373 UPPER GASTROINTESTINAL SAFETY AND TOLERABILITY PROFILE OF ONCE-MONTHLY ORAL IBANDRONATE: MOBILE 2-YEAR ANALYSIS

P. D. Delmas*¹, M. Stone², J. A. Stakkestad³, C. Leigh⁴, A. V. Hiltbrunner⁴, A. Burdeska⁴, C. Cooper⁵
¹Claude Bernard University and INSERM Research Unit 403, Lyon, France, ²Llandough Hospital, Cardiff, United Kingdom, ³CECOR AS, Haugesund, Norway, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵MRC Epidemiology Resource Centre, Southampton, United Kingdom

P374 PRECISION AND ACCURACY OF THE LUNAR IDXA, A NEW FAN-BEAM DENSITOMETER

K. G. Faulkner¹, **P. R. Deman***², W. K. Wacker¹, K. P. Riewe¹, J. R. Franz¹, H. S. Barden¹
¹GE Healthcare, Lunar, Madison, United States, ²GE Healthcare, Lunar Europe, Diegem, Belgium

P375 VALIDITY AND RELIABILITY OF DXA FOR REGIONAL FAT MASS DISTRIBUTION ASSESSMENT

S. Di Gregorio*¹, L. Del Rio¹, L. Ibañez², C. Sole¹, A. Ferrer², E. Bonel¹, J. Rosales¹
¹CETIR, Centre Mèdic, ²Hospital San Juan, De Dios, Barcelona, Spain

P376 IDENTIFICATION OF VERTEBRAL DEFORMITIES USING DUAL X-RAY ABSORPTIOMETRY (DXA): AN ITALIAN MULTICENTRIC STUDY

D. Diacinti*¹, C. Francucci², C. Fiore³, P. Pennisi³, M. Rossini⁴, A. Barone⁵, A. Giusti⁵, T. Bartalena⁶, R. Del Fiacco⁷, S. Minisola¹, E. D'Erasmus¹, G. Mazzuoli¹
¹Department of Clinical Sciences, University La Sapienza, Rome, ²Department of Endocrinology, University, Ancona, ³Department of Internal Medicine, University, Catania, ⁴Department of Internal Medicine, University, Verona, ⁵Geriatric, Hospital Galliera, Genova, ⁶Geriatric, General Hospital, Imola, ⁷Department of Clinical Sciences, University La Sapienza, Rome, Italy

P377 EFFECTS OF 12 MONTHS GROWTH HORMONE ADMINISTRATION ON MARKERS OF BONE TURNOVER AND PHOSPHOCALCIUM METABOLISM IN WOMEN WITH ESTABLISHED OSTEOPOROSIS

B. H. Durham*¹, F. Joseph², A. M. Ahmed², H. D. White², A. Joshi², J. P. Vora², W. D. Fraser¹
¹Clinical Biochemistry and Metabolic Medicine, ²Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool, United Kingdom

P378 PREVALENCE OF VITAMIN D INSUFFICIENCY IN DANISH ADULTS WITH FRAGILITY HIP FRACTURES

M. Bogh¹, **P. Eiken***²
¹Orthopaedic Surgery, ²Endocrinology, Hillerød Hospital, Hillerød, Denmark

P379 COMPARISON OF SERUM TARTRATE-RESISTANT ACID PHOSPHATASE ASSAYS FOR MONITORING ALENDRONATE TREATMENT

K. M. Fagerlund*¹, A. J. Janckila², H. Ylipahkala¹, S. L. Tiitinen³, L. T. Yam², H. K. Väänänen¹, J. M. Halleen⁴
¹Department of Anatomy, University of Turku, Institute of Biomedicine, Turku, Finland, ²Special Hematology Laboratory, Veterans Affairs Medical Center, Louisville, United States, ³Finnish Red Cross, Blood Service, Helsinki, ⁴Pharmatest Services Ltd, Turku, Finland

P380 VITAMIN D INADEQUACY IN PATIENTES WHO ARE SCREENED FOR OSTEOPOROSIS

D. Fernández-García*¹, R. Reyes-García¹, G. Alonso¹, P. Rozas¹, A. Sebastián-Ochoa¹, M. Ruiz-Requena², M. Muñoz-Torres¹
¹Bone Metabolic Unit, Endocrinology Division, ²Biochemistry Department, University Hospital San Cecilio., Granada, Spain

P381 VOLUMETRIC BONE MINERAL DENSITY DISTRIBUTION IN LONG BONES AFFECTED OR NOT BY GRAVITY IN 250 NORMAL MEN AND PRE- AND POST-MENOPAUSAL WOMEN. A PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY STUDY

G. R. COUNTRY¹, R. F. Capozza¹, S. Feldman¹, S. E. Ferretti¹, M. V. Ferretti¹, G. Marchetti¹, **J. L. Ferretti***²

¹Center for P-Ca Metabolism Studies, Natl. Univ. of Rosario, ²Center for P-Ca Metabolism Studies, Natl. Univ. of Rosario, Rosario, Argentina

P382 ALENDRONATE INHIBITS THE DEVELOPMENT OF OSTEOPENIA INDUCED BY CYCLOSPORINE OR TACROLIMUS ADMINISTRATION IN RATS

U. Cegiela¹, M. Pytlik¹, **J. Folwarczna***¹, I. Kaczmarczyk-Sedlak¹, B. Nowinska¹, L. Sliwinski¹, W. Janiec¹

¹Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

P383 THE EFFECTS OF RALOXIFENE AND METHOTREXATE ON THE MECHANICAL PROPERTIES OF THE FEMUR IN MALE RATS

B. Nowinska¹, U. Cegiela¹, **J. Folwarczna***¹, M. Pytlik¹, I. Kaczmarczyk-Sedlak¹, L. Sliwinski¹, W. Janiec¹

¹Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

P384 EFFECT OF CYCLOSPORINE ON BONE REMODELING IN RATS

M. Pytlik¹, U. Cegiela¹, **J. Folwarczna***¹, L. Sliwinski¹, B. Nowinska¹, I. Kaczmarczyk-Sedlak¹, W. Janiec¹

¹Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

P385 EFFECT OF RALOXIFENE AND LOW-DOSE TACROLIMUS ON BONE HISTOMORPHOMETRIC PARAMETERS IN MALE RATS

I. Kaczmarczyk-Sedlak¹, **J. Folwarczna***¹, U. Cegiela¹, B. Nowinska¹, M. Pytlik¹, W. Janiec¹, L. Sliwinski¹

¹Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

P386 EFFECTS OF RALOXIFENE ON THE OSSEOUS SYSTEM OF MALE RATS

J. Folwarczna*¹, L. Sliwinski¹, U. Cegiela¹, M. Pytlik¹, I. Kaczmarczyk-Sedlak¹, B. Nowinska¹, W. Janiec¹

¹Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

P387 EFFECT OF CONCURRENT ADMINISTRATION OF CYCLOSPORINE AND RALOXIFENE ON THE SKELETAL SYSTEM OF MALE RATS

M. Pytlik¹, B. Nowinska¹, **J. Folwarczna***¹, U. Cegiela¹, I. Kaczmarczyk-Sedlak¹, L. Sliwinski¹, W. Janiec¹

¹Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

P388 NERIDRONATE IN THE TREATMENT OF THALASSEMIA-INDUCED OSTEOPOROSIS.

A. Gaudio*¹, N. Morabito¹, A. Lasco¹, A. Xourafa¹, I. Macri¹, M. Atteritano¹, A. Catalano¹, D. Maisano¹, E. Morini¹, F. Franchina¹, A. Meo², N. Frisina¹

¹Dept. Internal Medicine, ²Dept. of Pediatrics, AOU, Messina, Italy

P389 THE PREVALENCE OF VITAMIN D INSUFFICIENCY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS BEFORE AND AFTER 12 MONTHS OF TREATMENT WITH CA AND VITAMIN D

A. E. Georgiadis*¹, F. Papadopoulou¹

¹Osteoporosis Center, LITO Gynecological Hospital, Athens, Greece

P390 EFFECTS OF CREATINE, GLUCOSE, AND CELL-CELL CONTACTS ON NORMAL AND OSTEOPOROTIC HUMAN OSTEOBLAST-LIKE CELLS IN VITRO

I. Gerber*¹, H. Gerber¹, T. Wallimann¹

¹Institute of Cell Biology, ETH Zurich, Zurich, Switzerland

P391 TWO YEARS OF ALENDRONATE AND CALCITONIN TREATMENTS IN POSTMENOPAUSAL OSTEOPOROSIS

F. Sendur*¹, G. Gurer¹, G. Bozbas¹, E. Tastaban¹

¹Physical Medicine and Rehabilitation, Adnan Menderes University Medical School, AYDIN, Turkey

P392 EFFECTS OF RALOXIFENE AND CALCITONIN TREATMENTS ON BONE MINERAL DENSITY IN POSTMENOPAUSAL OSTEOPOROSIS AFTER ONE YEAR

G. Gurer¹, F. Sendur*¹, A. Aydeniz¹, H. Aydemir¹

¹Physical Medicine and Rehabilitation, Adnan Menderes University Medical School, AYDIN, Turkey

P393 EVALUATION OF DXA SPINE, HIP AND DUAL HIP PRECISION USING THE PRODIGY

P. Hadji*¹, V. Ziller¹, M. Bauer¹, M. Gottschalk¹, A. Kauka¹

¹Gyn. Endocrinology, Reproductive Medicine and Osteoporosis, University Hospital of Giessen and Marburg, Campus Marburg, Marburg, Germany

P394 ARE TROCHANTERIC BMD MEASUREMENTS CAPABLE OF REPLACING THE VERTEBRAL ONES ?

D. Hadjidakis*¹, A. Mylonakis¹, I. I. Androulakis¹, A. Papaefstathiou¹, S. A. Raptis¹

¹2nd Department of Internal Medicine Propaedeutic, Research Institute, Attikon and Evgenidion University Hospitals, Athens University, Athens, Greece

P395 ROLE OF PROSTAGLANDINS IN THE ANABOLIC EFFECTS OF STRONTIUM RANELATE

S. Choudhary*¹, P. Halbout², C. Alander¹, L. Raisz¹, C. Pilbeam¹

¹UConn Center for Osteoporosis, University of Connecticut Health, Farmington, United States,

²Rheumatology Division, Groupe Servier, Courbevoie, France

P396 BONE MINERAL DENSITY AND HEALT RELATED QUALITY OF LIFE IN YOUNG ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS

H. Hamalainen*¹, M. Arkela-Kautainen¹, J. Haapasaari¹, H. Kautiainen¹, A. Kotaniemi¹, M. Leirisalo-Repo²

¹Rheumatology, Rheumatism Foundation Hospital, Heinola, ²Rheumatology, Helsinki University Hospital, Helsinki, Finland

P397 RELATIONSHIPS BETWEEN BONE ANABOLIC, PROTEOANABOLIC AND LIPOLYTIC EFFECTS OF GROWTH HORMONE (GH) REPLACEMENT IN GH DEFICIENT ADULTS

V. Hana¹, J. J. Stepan*¹

¹3rd Department of Internal Medicine, Charles University Faculty of Medicine, Prague, Czech Republic

P398 APPLICATION OF A TRIAGE APPROACH FOR THE DIAGNOSIS OF OSTEOPOROSIS: RISK INDICES AND PERIPHERAL BONE DENSITOMETRY

E. J. Harrison*¹, J. E. Adams¹

¹Clinical Radiology, The University of Manchester, Manchester, United Kingdom

P399 RESULTS FROM A 3-YEAR STUDY DESIGNED TO EVALUATE THE EFFECT OF SODIUM ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN

J. Z. Ilich*¹, R. A. Brownbill², A. H. N. Cillessen³

¹Nutrition, Food and Exercise Sciences, Florida State University, Tallahassee, ²Nutritional Sciences,

³Psychology, University of Connecticut, Storrs, United States

P400 THE CARE GAP IN FAMILY PHYSICIANS' AWARENESS OF KEY RISK FACTORS FOR FRACTURE AND THE APPROPRIATE USE OF BONE MINERAL DENSITY (BMD) TESTING FOLLOWING A COMPREHENSIVE OSTEOPOROSIS EDUCATIONAL INTERVENTION: CANADIAN QUALITY CIRCLE (CQC) NATIONAL PROJECT

A. Papaioannou*¹, G. Ioannidis¹, B. Kvern², A. Hodsman³, L. Thabane⁴, A. Gafni⁴, D. Johnstone⁵, C. Crowley⁶, N. Plumley⁷, J. D. Adachi¹

¹Medicine, McMaster University, Hamilton, ²Medicine, University of Manitoba, Winnipeg, ³Medicine, University of Western Ontario, London, ⁴Clinical Epidemiology and Biostatistics, McMaster

University, Hamilton, ⁵National Professional Relations Manager, ⁶Medical and Technical Affairs,

⁷CQC Project Manager, Procter and Gamble Pharmaceuticals, Toronto, Canada

P401 FAMILY PHYSICIANS' UTILIZATION OF BONE MINERAL DENSITY (BMD) TESTING, AND THE RATE THAT BISPHOSPHONATES ARE PRESCRIBED TO THEIR PATIENTS WITH KEY RISK FACTORS FOR FRACTURE: CANADIAN QUALITY CIRCLE (CQC) PILOT PROJECT

G. Ioannidis*¹, A. Papaioannou¹, B. Kvern², A. Hodsmann³, D. Johnstone⁴, C. Crowley⁵, N. Plumley⁶, J. D. Adachi¹

¹Medicine, McMaster University, Hamilton, ²Medicine, University of Manitoba, Winnipeg, ³Medicine, University of Western Ontario, London, ⁴National Professional Relations Manager, ⁵Medical and Technical Affairs, ⁶CQC Project Manager, Procter and Gamble Pharmaceuticals, Toronto, Canada

P402 THE RATE THAT FAMILY PHYSICIANS PRESCRIBE OSTEOPOROSIS MEDICATIONS TO THEIR PATIENTS WITH FRACTURES: CANADIAN QUALITY CIRCLES (CQC) NATIONAL PROJECT

A. Hodsmann*¹, G. Ioannidis², A. Papaioannou², B. Kvern³, L. Thabane⁴, A. Gafni⁴, D. Johnstone⁵, C. Crowley⁶, N. Plumley⁷, J. D. Adachi²

¹Medicine, University of Western Ontario, ²Medicine, McMaster University, Hamilton, ³Medicine, University of Manitoba, Winnipeg, ⁴Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ⁵National Professional Relations Manager, ⁶Medical and Technical Affairs, ⁷CQC Project Manager, Procter and Gamble Pharmaceuticals, Toronto, Canada

P403 FAMILY PHYSICIANS' AWARENESS OF HEIGHT LOSS AND KYPHOSIS IN THEIR PATIENTS AND THE APPROPRIATE USE OF X-RAY ORDERING FOLLOWING A MULTIFACETED OSTEOPOROSIS EDUCATIONAL INTERVENTION: CANADIAN QUALITY CIRCLE (CQC) NATIONAL PROJECT

B. Kvern*¹, G. Ioannidis², A. Hodsmann³, A. Papaioannou², L. Thabane⁴, A. Gafni⁴, D. Johnstone⁵, C. Crowley⁶, N. Plumley⁷, J. D. Adachi²

¹Medicine, University of Manitoba, Winnipeg, ²Medicine, McMaster University, Hamilton, ³Medicine, University of Western Ontario, London, ⁴Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ⁵National Professional Relations Manager, ⁶Medical and Technical Affairs, ⁷CQC Project Manager, Procter and Gamble Pharmaceuticals, Toronto, Canada

P404 EFFECT OF MILK BASIC PROTEIN (MBP) SUPPLEMENTATION ON BONE MASS AND BONE TURNOVER IN JAPANESE YOUNG ADULT AND PERIMENOPAUSAL WOMEN

A. Itabashi*¹, K. Uenishi², T. Koyama³, S. Aoe⁴, Y. Toba⁵, Y. Takada⁶

¹Clinical Laboratory Medicine, Saitama Mecilas School, Moroyama, ²Laboratory of Physiological Nutrition, Kagawa Nutrition University, Sakado, ³Clinical Laboratory Medicine, Koyama Takao Clinic, ⁴Home Economics, Otsuma Women's University, ⁵Functional Products Business Development, ⁶Product Planning Department, Snow Brand Milk Products Co., Tokyo, Japan

P405 EFFECT OF TEAM-BASED THERAPY ON HEALTH -RELATED BEHAVIOUR OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

S. Kalra*¹, B. Kalra², J. Baweja³, K. Chawla⁴, P. Batra⁵

¹Endocrinology, ²Gynaecology, ³Physiotherapy, ⁴Psychology, ⁵Counselling, Bharti Hospital, Karnal, India

P406 PHYSIOTHERAPY IN OSTEOPOROSIS PATIENTS: UTILIZATION AND BENEFITS

S. Kalra*¹, J. Baweja², B. Kalra³

¹Endocrinology, ²Physiotherapy, ³Gynaecology, Bharti Hospital, Karnal, India

P407 AGE RELATED CHANGES IN BONE MINERAL DENSITY IN HEALTHY INDIAN ROLE OF SEX STEROIDS

I. M. Khatkhatay*¹, K. K. V. Venkat¹, M. P. Desai¹

¹Division of Molecular Immunodiagnosics, National Institute For Research in Reproductive Health, Mumbai, India

P408 TUMORAL CALCINOSIS OF THE HAND

H. Kim*¹, M. Joo¹, S. Chang¹, J. Kwak¹, J. Suh², Y. Kim³

¹Pathology, ²Orthopaedic surgery, ³Radiology, Inje University Ilsan Paik Hospital, Koyang, South Korea

P409 INSULIN RESISTANCE IN POSTMENOPAUSAL WOMEN: THE BENEFIT OF VITAMIN D SUPPLEMENTATION

Z. Krivosikova*¹, V. Spustova¹, K. Stefikova¹, R. Dzurik¹

¹Department of clinical and experimental pharmacotherapy, Slovak Medical University, Bratislava, Slovakia

P410 A COMPARISON OF GE HEALTHCARE LUNAR PRODIGY AND IDXA DENSITOMETERS

D. Krueger*¹, M. Checovich¹, N. Vallarta-Ast¹, D. Gemar¹, R. Clodfelter¹, N. Binkley¹

¹Osteoporosis Clinical Research Program, University of Wisconsin, Madison, United States

P411 RISEDRONATE 35 MG PLUS CALCIUM COMBINATION PACKAGE IMPROVES COMPLIANCE AND INFLUENCES PATIENT'S PREFERENCE

H. Kruse*¹, J. D. Ringe²

¹Abteilung für Nephrologie und Osteologie, Universitäts-Krankenhaus Eppendorf, Hamburg,

²Medizinische Klinik IV, Klinikum Leverkusen, D-51375 Leverkusen, Germany

P412 SYNERGISTIC EFFECTS OF AGOUTI PROTEIN AND ROSIGLITAZONE ON BONE LOSS IN A MURINE MODEL OF OBESITY AND TYPE 2 DIABETES

O. P. Lazarenko¹, L. J. Suva², **B. Lecka-Czernik***¹

¹Geriatrics, ²Orthopedics, University of Arkansas for Medical Sciences, Little Rock, United States

P413 RANKL INHIBITION BY OPG PREVENTS BONE LOSS AND PRESERVES TRABECULAR ARCHITECTURE IN ORCHIECTOMIZED RATS

X. Li*¹, M. S. Ominsky¹, F. Asuncion¹, M. Grisanti¹, H. L. Tan¹, K. S. Warmington¹, P. J. Kostenuik¹

¹Metabolic Disorders, Amgen Inc., Thousand Oaks, United States

P414 UTILITY VALUE OF OSTEOPOROSIS SCREENING WITH FRACTURE RISK EVALUATION IN KOREAN WOMEN

S. Y. Park¹, D. M. Kim¹, S. H. Lee¹, Y. M. Rhee¹, W. H. Choi², H. Choi³, J. G. Kim⁴, Y. S. Chung⁵, **S. Lim***¹

¹Department of Internal Medicine, College of Medicine, Yonsei University, ²Department of Internal Medicine, College of Medicine, Hanyang University, ³Department of Obstetrics and Gynecology, College of Medicine, Inje University, ⁴Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, ⁵Department of Internal Medicine, College of Medicine, Ajou University, Suwon, South Korea

P415 RESPONSE TO ONCE-MONTHLY AND DAILY ORAL IBANDRONATE IN THE MOBILE STUDY: 2-YEAR ANALYSIS

R. Lorenc*¹, R. Nuti², D. Doyle³, C. Hughes⁴, F. Sedarati⁴, A. Burdeska⁴, D. Felsenberg⁵

¹The Children's Memorial Institute, Warsaw, Poland, ²University of Siena, Siena, Italy, ³Whipps Cross University Hospital, London, United Kingdom, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Charité-University Medicine Berlin, Berlin, Germany

P416 PREDICTION OF FEMORAL HEAD COLLAPSE FOR PATIENTS WITH FEMORAL HEAD NECROSIS USING BMD AND MRI

H. Z. Ma*¹

¹Department of Orthopaedic Surgery, Shanghai Sixth People hospital Shanghai Jiaotong University, Shanghai, China

P417 STRONTIUM RANELATE STIMULATES MURINE OSTEOBLAST REPLICATION INDEPENDENTLY OF CALCIUM SENSING RECEPTOR-MEDIATED ERK1/2 ACTIVATION

O. Fromigé¹, A. Barbara¹, E. Hay¹, C. Petrel², E. Traiffort², M. Ruat², **P. J. Marie***¹

¹Osteoblast biology and pathology laboratory, Inserm U606 and University Paris 7, Hôpital

Lariboisière, Paris, ²Cell and Molecular Neurobiology Laboratory, UPR 940 CNRS, Gif-sur-Yvette, France

P418 DOSE RESPONSE OF LEPTIN ON BONE METABOLISM: A PUTATIVE ROLE FOR ENERGY INTAKE AND IGF-I PATHWAY

A. Martin*¹, V. David¹, L. Malaval¹, M. Lafage-Proust¹, L. Vico¹, T. Thomas¹
¹LBTO INSERM366, Faculté de médecine, Saint-Etienne, France

P419 ICV LEPTIN ADMINISTRATION ALTERS BONE METABOLISM AND HORMONAL STATUS IN RATS

A. Martin*¹, V. David¹, L. Vico¹, T. Thomas¹
¹LBTO INSERM366, Faculté de médecine, Saint-Etienne, France

P420 THE USEFULNESS OF PERIPHERAL BONE DENSITOMETRY IN THE DIAGNOSIS OF OSTEOPOROSIS IN PATIENTS WITH COELIAC DISEASE

T. Masud*¹, B. Lobo², D. Pearson³, K. Teahon², W. Goddard²
¹Medicine, Nottingham City Hospital and University of Derby, ²Medicine, ³Medical Physics, Nottingham City Hospital, Nottingham, United Kingdom

P421 THE TERIPARATIDE IN THE THERAPY OF THE SENILE SEVERE OSTEOPOROSIS

D. Maugeri*¹, M. Rizzotto², E. Russo³, G. Reina⁴, P. Panebianco⁵, R. Castelli⁶, G. G. Russo⁶, S. Strano⁶, S. Grasso⁶
¹Department of Senescent, Urological and Neurological Sciences, ²Department of of Senescent, Urological and Neurological Sciences, University of Catania, Catania, ³Servizio MOC, Ospedale di Patti, Messina, ⁴Servizio MOC, Ospedale di Adrano, ⁵Department of Senescent, Urological and Neurological Sciences, University of Catania, Catania, ⁶Department of Senescent, Urological and Neurological Sciences, University of Catania, Messina, Italy

P422 SHORT TERM HORMONE REPLACEMENT THERAPY RESULTS IN LONG TERM GAINS IN BONE MINERAL DENSITY

E. T. Middleton*¹, S. M. Doherty¹, S. A. Steel¹
¹Centre for Metabolic Bone Disease, Hull Royal Infirmary, Hull, United Kingdom

P423 DOES PREVIOUS TREATMENT WITH BISPHOSPHONATES IMPAIR THE RESPONSE TO TERIPARATIDE?

E. T. Middleton*¹, P. Albertazzi¹, M. Bottazzi²
¹Centre for Metabolic Bone Disease, Hull Royal Infirmary, Hull, United Kingdom, ²Department of Applied Health Sciences, University of Pavia, Pavia, Italy

P424 DENOSUMAB (AMG 162) TREATMENT FOR TWO YEARS INCREASES BMD AND REDUCES MARKERS OF BONE TURNOVER IRRESPECTIVE OF BASELINE WEIGHT AND BMI

P. D. Miller*¹, E. M. Lewiecki², M. Peacock³, M. A. Bolognese⁴, A. Wang⁵, Y. Liu⁵, L. A. Fitzpatrick⁵
¹Colorado Center for Bone Research, Lakewood, CO, ²New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, ³Indiana University School of Medicine, Indianapolis, IN, ⁴Bethesda Health Research Center, Bethesda, MD, ⁵Amgen Inc., Thousand Oaks, CA, United States

P425 PTH(1-84) PREVENTS VERTEBRAL FRACTURES IN POST MENOPAUSAL WOMEN WITH HIGHER FRACTURE RISK: RESULTS FROM THE TOP STUDY

P. Miller*¹, S. L. Greenspan²
¹Colorado Center for Bone Research, University of Colorado Health Sciences Center, Denver, ²Osteoporosis Center, University of Pittsburgh, Pittsburgh, United States

P426 NOVEL FLUOROCHROME MARKERS TO DETECT MICRODAMAGE IN BONE

S. Mohsin*¹, T. C. Lee¹, R. Parkesh², T. Gunnlaugsson²
¹Anatomy, Royal College of Surgeons in Ireland, ²Chemistry, Trinity College, Dublin, Ireland

P427 EFFECTS OF INTRAVENOUS PAMIDRONATE ON BONE LOSS AFTER LIVER TRANSPLANTATION

A. Monegal*¹, M. Navasa², M. Suarez³, S. Suarez Lopez⁴, F. Garcia Gonzalez⁵, T. Serrano⁶, G. Clemente⁷, F. Casafont⁸, M. De la Mata⁹, C. Barrios¹⁰, P. Peris¹, N. Guañabens¹
¹Rheumatology Service, ²Liver Unit, Hospital Clinic Barcelona, Barcelona, ³Transplantation Unit, Hospital Cruces, Bilbao, ⁴Transplantation Unit, Hospital Juan Canalejo, La Coruña, ⁵Transplantation Unit, Hospital Ramon y Cajal, Madrid, ⁶Transplantation Unit, Hospital Lozano Blesa, Zaragoza, ⁷Transplantation Unit, Hospital Gregorio Marañón, Madrid, ⁸Transplantation Unit, Hospital Marques de Valdecilla, Santander, ⁹Transplantation Unit, Hospital Reina Sofia, Cordoba, ¹⁰Transplantation Unit, Hospital Puerta de Hierro, Madrid, Spain

P428 PREVALENCE OF VITAMIN D INADEQUACY IN OSTEOPOROTIC HIP FRACTURE PATIENTS IN S.E. LONDON

C. Moniz*¹, T. Dew¹, T. Dixon²
¹Clinical Biochemistry, Kings College Hospital, London, ²JB Medical, Sudbury, Suffolk, United Kingdom

P429 BONE TURNOVER INCREASES IN EARLY POSTMENOPAUSAL COMPARE TO PREMENOPAUSAL WOMEN

L. Navarro*¹, J. Blázquez², M. Cháfer¹, F. Mateos², E. Almar³, J. Del Pino⁴
¹Clinical Chemistry, ²Internal Medicine, University Hospital, ³Epidemiology, Health Department, Albacete, ⁴Rheumatology, University Hospital, Salamanca, Spain

P430 INDIRECT COMPARISON OF ANTI-VERTEBRAL FRACTURE EFFICACY AMONG AVAILABLE THERAPIES: A BAYESIAN ANALYSIS

N. D. Nguyen*¹, J. A. Eisman¹, T. V. Nguyen¹
¹Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney, Australia

P431 ON THE ASSOCIATION BETWEEN STATIN AND FRACTURE: A BAYESIAN CONSIDERATION

C. Y. Wang¹, **N. D. Nguyen***¹, J. A. Eisman¹, T. V. Nguyen¹
¹Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney, Australia

P432 A GROUP-BASED EDUCATION PROGRAMME INCREASES KNOWLEDGE ON OSTEOPOROSIS AND ADHERENCE TO PHARMACOLOGICAL TREATMENT. INTERIM ANALYSIS FROM A RANDOMISED TRIAL.

D. Nielsen*¹, W. Nielsen², B. Knold¹, N. Nissen¹, J. Ryg¹, A. R. Madsen¹, K. Brixen¹
¹Department of Endocrinology, Odense University Hospital, ²Department of Physiotherapy, Odense University Hospital, Odense, Denmark

P433 INTRODUCTION OF A NEW GUIDELINE FOR ORTHOPAEDIC SURGEONS AFTER PATIENTS SUFFERS FRACTURE FROM LOW-ENERGY TRAUMA

N. Nissen*¹, H. Andersen¹, B. Risom¹, E. Schlosser¹, L. Andersen¹, P. Hermann², S. Schmidt¹
¹Orthopaedics, ²Medicine, Kolding Sygehus, Kolding, Denmark

P434 PERFORMANCE OF THE LUNAR IDXA IMAGING DENSITOMETER IN NORMAL AND OBESE SUBJECTS

M. K. O'Connor*¹, D. Enright¹
¹Radiology, Mayo Clinic, Rochester, United States

P435 EFFECTS OF RALOXIFENE WITH FLUORIDE ON SPINAL BMD IN KOREAN POSTMENOPAUSAL WOMEN.

H. Oh¹, B. Yoo², **I. Joo***¹, K. Kim³
¹Family Medicine, Sungkyunkwan University, Samsung Cheil Hospital, Seoul, ²Family Medicine, Konyang University, Daejeon, ³Family Medicine, Ajou University, Suwon, South Korea

P436 CHANGES OF BMD AFTER 1-YEAR TREATMENT WITH RISEDRONATE COMPARED WITH RALOXIFENE IN KOREAN POSTMENOPAUSAL WOMEN

H. Oh*¹, K. Kim², K. Cho³, H. Lee⁴, S. Lee⁵
¹Family Medicine, Sungkyunkwan University, Samsung Cheil Hospital, ²Family Medicine, Catholic

University, ³Family Medicine, National Health Insurance Hospital, ⁴Family Medicine, Ewha University, ⁵Family Medicine, Ewha university, Seoul, South Korea

P437 SUPERIORITY OF A COMBINED TREATMENT OF ALFACALCIDOL AND ALENDRONATE COMPARED TO THE MONOTHERAPIES IN POSTMENOPAUSAL OSTEOPOROSIS

K. Ones¹, E. Schacht²

¹Physical Medicine and Rehabilitation, Istanbul Physical Medicine and Rehabilitation Training and Research Hospital, Istanbul, Turkey, ²Rheumatology and Rehabilitation, University Clinic Balgrist, Zurich, Switzerland

P438 IMPROVING COMPLIANCE AND PERSISTENCE WITH DRUG THERAPIES FOR OSTEOPOROSIS

N. Ota*¹, H. Ito²

¹Orthopedics, Mitsubishi Heavy Industries Okurayama Hospital, Yokohama, ²Orthopedics, Nippon Medical School, Tokyo, Japan

P439 THE BISPHTHONATE TREATMENT CARE GAP IN COMMUNITY DWELLING MEN AND WOMEN WHO HAVE INCIDENT FRAGILITY FRACTURES: THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY (CAMOS)

G. Ioannidis*¹, A. Papaioannou¹, A. Tenenhouse², Y. Gao³, C. Berger³, J. C. Prior⁴, S. M. Kaiser⁵, D. A. Hanley⁶, J. P. Brown⁷, W. P. Olszynski⁸, T. M. Murray⁹, T. Anastassiades¹⁰, S. Kirkland¹¹, C. Joyce¹², S. Poliquin¹³, N. Kreiger¹⁴, S. Davison⁸, C. Kennedy¹, K. Siminoski¹⁵, D. Goltzman², J. Adachi¹

¹Medicine, McMaster University, Hamilton, ²Medicine, ³CaMos Analysis Centre, McGill University, Montreal, ⁴Medicine, Endocrinology, University of British Columbia, Vancouver, ⁵Medicine, Dalhousie University, Halifax, ⁶Medicine, University of Calgary, Calgary, ⁷Medicine, Laval University, Ste-Foy, ⁸Medicine, University of Saskatchewan, Saskatoon, ⁹Medicine, University of Toronto, Toronto, ¹⁰Medicine, Division of Rheumatology, Queen's University, Kingston, ¹¹Community Health and Epidemiology, Dalhousie University, Halifax, ¹²Medicine, Memorial University, St. John's, ¹³CaMos National Coordinating Centre, McGill University, Montreal, ¹⁴Public Health Sciences, University of Toronto, Toronto, ¹⁵Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Canada

P440 CORRELATIONS BETWEEN STATIC TRABECULAR PARAMETERS MEASURED BY QUANTITATIVE COMPUTER TOMOGRAPHY OR HISTOMORPHOMETRY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

D. Michalská*¹, C. C. Glüer², J. J. Stepan¹, I. Pavo³, A. Sipos³, H. Petto³, D. B. Burr⁴, M. Sato³, J. Neuwirth⁵, H. Dobnig⁶

¹Department of Internal Medicine 3, Charles University, Faculty of Medicine, Prague, Czech Republic, ²Medical Physics, Department of Diagnostic Radiology, University Hospital Schleswig-Holstein, Kiel, Germany, ³Lilly Research Laboratories, Eli Lilly and Company, ⁴Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, United States, ⁵Department of Radiology, Charles University, Faculty of Medicine, Prague, Czech Republic, ⁶Department of Internal Medicine, Medical University, Graz, Austria

P441 LONGITUDINAL CHANGES IN QUANTITATIVE ULTRASOUND IN POSTMENOPAUSAL HEALTHY WOMEN

J. M. Lavado*¹, M. L. Canal¹, M. T. Rodríguez¹, J. F. Calderón¹, J. D. Pedrera¹

¹Nursing Department, Universidad de Extremadura, Cáceres, Spain

P442 COMPARISON OF DIGITAL X-RAY RADIOGRAMMETRY (DXR) AND DUAL-ENERGY X-RAY ABSORPTIOMETRY (DXA) FOR QUANTIFICATION BONE MINERAL DENSITY IN RHEUMATOID ARTHRITIS (RA)

J. Böttcher*¹, A. Pfeil¹, G. Lehmann², M. L. Schäfer¹, A. Petrovitch¹, A. Malich³, W. A. Kaiser¹, G. Hein², G. Wolf²

¹Friedrich-Schiller-University Jena, Institute of Diagnostic and Interventional Radiology, ²Friedrich-Schiller-University Jena, Clinic of Internal Medicine III, Jena, ³Sued-Harz Klinikum, Department of Radiology, Nordhausen, Germany

P443 QUANTIFICATION OF JUXTA-ARTICULAR DEMINERALIZATION IN RHEUMATOID ARTHRITIS BY DIGITAL X-RAY RADIOGRAMMETRY AND PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY

J. Böttcher*¹, A. Pfeil¹, G. Lehmann², B. Heinrich¹, M. L. Schäfer¹, A. Petrovitch¹, A. Malich³, W. A. Kaiser¹, G. Hein², G. Wolf²

¹Friedrich-Schiller-University Jena, Institute of Diagnostic and Interventional Radiology, ²Friedrich-Schiller-University Jena, Clinic of Internal Medicine III, Jena, ³Sued-Harz Klinikum, Department of Radiology, Nordhausen, Germany

P444 EVALUATION OF DISEASE ACTIVITY DEPENDENT CORTICAL BONE LOSS IN RHEUMATOID ARTHRITIS

A. Pfeil*¹, J. Böttcher¹, H. J. Mentzel¹, M. L. Schäfer¹, G. Lehmann², M. Schmidt², A. Petrovitch¹, A. Malich³, W. A. Kaiser¹, G. Wolf⁴, G. Hein²

¹Friedrich-Schiller-University Jena, Institute of Diagnostic and Interventional Radiology, ²Friedrich-Schiller-University Jena, Clinic of Internal Medicine III, Jena, ³Sued-Harz Klinikum, Department of Radiology, Nordhausen, ⁴Friedrich-Schiller-University Jena, Department of Radiology, Jena, Germany

P445 PRECISION OF DIGITAL X-RAY RADIOGRAMMETRY (DXR)

A. Pfeil*¹, J. Böttcher², G. Lehmann³, M. L. Schäfer², A. Petrovitch², W. Linß⁴, A. Malich⁵, W. A. Kaiser², G. Wolf³, G. Hein³

¹Friedrich-Schiller-University, ²Friedrich-Schiller-University Jena, Institute of Diagnostic and Interventional Radiology, ³Friedrich-Schiller-University Jena, Clinic of Internal Medicine III, ⁴Friedrich-Schiller-University Jena, Institute of Anatomy I, ⁵Sued-Harz Klinikum, Department of Radiology, Jena, Germany

P446 INITIAL RESULTS OF REPRODUCIBILITY FOR DUAL X-RAY AND LASER (DXL)

A. Pfeil*¹, J. Böttcher², G. Lehmann³, M. L. Schäfer¹, A. Kramer¹, A. Petrovitch¹, M. Schmidt¹, A. Malich⁴, W. A. Kaiser¹, G. Wolf³, G. Hein³

¹Friedrich-Schiller-University Jena, Institute of Diagnostic and Interventional Radiology, ²Friedrich-Schiller-University Jena, Friedrich-Schiller-University Jena, ³Friedrich-Schiller-University Jena, Clinic of Internal Medicine III, Jena, ⁴Sued-Harz Klinikum, Department of Radiology, Nordhausen, Germany

P447 EVALUATION OF IMAGE CAPTURING PARAMETERS ON PRECISION OF DIGITAL X-RAY RADIOGRAMMETRY (DXR)

J. Böttcher*¹, A. Pfeil¹, G. Lehmann², M. L. Schäfer¹, A. Petrovitch¹, A. Malich³, W. Linß⁴, W. A. Kaiser¹, G. Wolf², G. Hein²

¹Friedrich-Schiller-University Jena, Institute of Diagnostic and Interventional Radiology, ²Friedrich-Schiller-University Jena, Clinic of Internal Medicine III, Jena, ³Sued-Harz Klinikum, Department of Radiology, Nordhausen, ⁴Friedrich-Schiller-University Jena, Institute of Anatomy I, Jena, Germany

P448 REPRODUCIBILITY OF EXA-3000 AS A NEW DUAL ENERGY X-RAY ABSORPTIOMETRY DEVICE FOR MEASUREMENT BONE MINERAL DENSITY ON RADIUS AND CALCANEUS

A. Pfeil*¹, J. Böttcher¹, M. L. Schäfer¹, G. Lehmann², M. Schmidt¹, A. Kramer¹, A. Petrovitch¹, A. Malich³, W. A. Kaiser¹, G. Hein², G. Wolf²

¹Friedrich-Schiller-University Jena, Institute of Diagnostic and Interventional Radiology, ²Friedrich-Schiller-University Jena, Clinic of Internal Medicine III, Jena, ³Sued-Harz Klinikum, Department of Radiology, Nordhausen, Germany

P449 REPRODUCIBILITY OF MULTI-SITE QUANTITATIVE ULTRASOUND FOR HEALTHY INDIVIDUALS AND PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS

A. Pfeil*¹, J. Böttcher¹, H. J. Mentzel¹, G. Lehmann², M. L. Schäfer¹, A. Kramer¹, A. Petrovitch¹, A. Malich³, W. A. Kaiser¹, G. Wolf², G. Hein²

¹Friedrich-Schiller-University, Institute of Diagnostic and Interventional Radiology, ²Friedrich-Schiller-University, Clinic of Internal Medicine III, Jena, ³Sued-Harz Klinikum, Department of Radiology, Nordhausen, Germany

P450 DIGITAL X-RAY RADIOGRAMMETRY - IMPLEMENTATION OF CORRECTION FACTORS OF CORTICAL THICKNESS, METACARPAL INDEX AND BONE MINERAL DENSITY

J. Böttcher*¹, A. Pfeil¹, M. L. Schäfer¹, G. Lehmann², A. Petrovitch¹, A. Malich³, W. Linß⁴, W. A. Kaiser¹, G. Wolf², G. Hein²

¹Friedrich-Schiller-University Jena, Institute of Diagnostic and Interventional Radiology, ²Friedrich-Schiller-University Jena, Clinic of Internal Medicine III, Jena, ³Sued-Harz Klinikum, Department of Radiology, Nordhausen, ⁴Friedrich-Schiller-University Jena, Institute of Anatomy I, Jena, Germany

P451 VERTEBROPLASTY AND KYPHOPLASTY IN OSTEOPOROTIC FRACTURES OF VERTEBRAL BODIES

R. Pflugmacher*¹

¹Centrum für Muskuloskeletale Chirurgie, Charité-Universitätsmedizin Berlin, Berlin, Germany

P452 RALOXIFENE EFFECTS ON BONE MARKERS, BONE MINERAL DENSITY, LIPID PROFILE AND BODY COMPOSITION IN POSTMENOPAUSAL WOMEN

C. Poiana*¹, L. Stoian²

¹Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania,

²Endocrinology, C.I.Parhon Institute of Endocrinology, Bucharest, Romania

P453 BONE LOSS IN WOMEN OF DIFFERENT AGE WITH RHEUMATOID ARTHRITIS

V. V. Povoroznjuk*¹

¹Physiology and Pathology of Locomotor Apparatus, Institute of Gerontology, Kiev, Ukraine

P454 ORAL IBANDRONATE REDUCES ACTIVATION FREQUENCY TO HEALTHY PREMENOPAUSAL LEVELS IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS

R. R. Recker*¹, K. M. Davis¹, M. J. Barger-Lux¹, R. P. Heaney¹, J. M. Lappe¹

¹Osteoporosis Research Center, Creighton University, Omaha, United States

P455 INTERMITTENT INTRAVENOUS IBANDRONATE INJECTIONS HAVE A SIMILAR BONE SAFETY PROFILE TO DAILY ORAL DOSING

R. R. Recker*¹, L. G. Ste-Marie², E. Czerwinski³, L. Rowell⁴, B. Bonvoisin⁴, D. Masanauskaitė⁴, D. Felsenberg⁵

¹Osteoporosis Research Center, Creighton University, Omaha, United States, ²., CHUM Hôpital St-Luc, Montreal, Canada, ³., Krakow Medical Centre, Krakow, Poland, ⁴., F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵., Charité-University Medicine Berlin, Berlin, Germany

P456 THE VIENNA TERIPARATIDE DATABASE

H. Resch*¹, C. Muschitz¹, J. Patsch¹, N. Pascher¹, E. Edlmayr¹, T. Woegerbauer¹

¹Medical Department II, St. Vincent Hospital, Vienna, Austria

P457 THERAPEUTIC EFFICACY OF RISEDRONATE IN MEN WITH OSTEOPOROSIS - CONSISTENT 61% RISK REDUCTION OF NEW VERTEBRAL FRACTURES AFTER THE FIRST AND SECOND YEAR OF RISEDRONATE THERAPY

J. D. Ringe*¹, A. Dorst², H. Faber²

¹Medizinische Klinik IV, Klinikum Leverkusen, ²Medizinische Klinik IV, Klinikum Leverkusen,, Leverkusen, Germany

P458 IDENTIFYING NON-RESPONDERS TO RISEDRONATE OR ALENDRONATE IN THE FOSAMAX® ACTONEL® COMPARISON TRIAL (FACT)

A. Sebba*¹, K. Saag², S. Bonnick³, E. Rosenberg⁴, E. Chen⁴, A. De Papp⁴

¹Clinical Research, Arthritis Associates, Palm Harbor, ²Clinical Research, University of Alabama, Birmingham, ³Clinical Research, CRC of North Texas, Denton, ⁴Clinical Research, Merck and Co., Inc., West Point, United States

P459 COMPARISON OF THE STATINE EFFECTS ON BONE MINERAL DENSITY AND BONE METABOLISM WITH CALCIUM AND VITAMIN D EFFECTS IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA

L. Y. Rozhinskaya*¹, N. Kryzhova¹, I. P. Ermakova², A. V. Iljin³, N. I. Sazonova⁴, G. A. Melnichenko⁵

¹Neuroendocrinology and Osteoporosis, National Research Center for Endocrinology of Russian Academy of Medical Science, ²Biochemical laboratory, Institut of Transplantology, ³Biochemical laboratory, ⁴Functional diagnostics, ⁵Institut of Clinical Endocrinology, National Research Center for Endocrinology of Russian Academy of Medical Science, Moscow, Russian Federation

P460 CHANGE IN BONE MASS DUE TO HYPERTHYROIDISM

D. Ruci*¹, F. Toti², V. Ruci³, A. Tafaj³

¹Department of Rheumatology and Bone Diseases, Mother Teresa University Hospital Tirana, Albania., ²Department of Endocrinology, Mother Teresa University Hospital, ³Department of Rheumatology and Bone Diseases, Mother Teresa University Hospital, Tirana, Albania

P461 ADHERENCE TO TREATMENT AND CHANGES IN VITAMIN D STATUS IN HIP FRACTURE PATIENTS – PARTICIPANTS OF POST-SURGICAL TREATMENT PROGRAM

E. Segal*¹, C. Zinman², B. Raz¹, S. Ish-Shalom¹

¹Metabolic Bone Disease Unit, ²Orthopedic Surgery, Rambam Health Care Campus, Haifa, Israel

P462 CHARACTERISTICS OF THE DIABETIC PATIENTS WITH HIP FRACTURES

E. Segal*¹, C. Zinman², V. Raichlin², B. Gurevich¹, A. Psavke¹, M. Ish-Shalom³, S. Ish-Shalom¹

¹Metabolic Bone Disease Unit, ²Orthopedic Surgery Department, Rambam Health Care Campus, Haifa, ³Internal Medicine Department, Sorasky Medical Center, Tel-Aviv, Israel

P463 IMPROVING THE MANAGEMENT OF PATIENTS WITH OSTEOPOROTIC FRACTURES: THE OMEN PROJECT

A. Lih¹, C. Nickolls¹, **M. J. Seibel***¹

¹Bone Research Programme, Anzac Research Institute, Sydney, Australia

P464 PATIENTS' PERCEPTION OF IMPORTANCE OF DIFFERENT ATTRIBUTES OF OSTEOPOROSIS MEDICATION: RESULTS FROM THE PREFER-INTERNATIONAL STUDY

J. Walliser*¹, S. Bolge², S. S. Sen³

¹Clinical de Metabolismo Oseo, Mineral del Hospital Angeles del Pedregal, Mexico City, Mexico, ²CHS, Consumer Health Sciences, Princeton, ³Outcomes Research, Merck, Whitehouse Station, United States

P465 EVALUATION OF PATIENTS' PREFERENCE FOR OSTEOPOROSIS MEDICATIONS: PREFER-INTERNATIONAL

J. Walliser*¹, S. Bolge², S. S. Sen³

¹Clinical de Metabolismo Oseo, Mineral del Hospital Angeles del Pedregal, Mexico City, Mexico, ²CHS, Consumer Health Services, Princeton, ³Outcomes Research, Merck, Whitehouse Station, United States

P466 COST-EFFECTIVENESS OF FOSAVANCE® IN THE TREATMENT AND PREVENTATION OF OSTEOPOROSIS IN THE UNITED KINGDOM AND THE NETHERLANDS

J. Jansen*¹, S. Gaugris², M. Van Genugten¹, S. S. Sen²

¹MV, MapiValues, Houten, Netherlands, ²Outcomes Research, Merck, Whitehouse Station, United States

P467 ASSOCIATIONS BETWEEN BONE MINERAL DENSITY USING DUAL ENERGY X-RAY ABSORPTIOMETRY AND BONE STRENGTH PROPERTIES USING PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY

K. M. Shedd¹, K. B. Hanson², D. L. Alekel², L. N. Hanson², M. D. VanLoan³

¹Department of Nutrition, University of California, Davis, ²Department of Food Science and Human Nutrition, Iowa State University, Ames, ³Western Human Nutrition Research Center, USDA, ARS, Davis, United States

P468 PARKINSON'S DISEASE AND OSTEOPOROSIS

M. Hussain¹, **T. Solanki***¹, S. C. Cooper¹, L. Pollock¹

¹Care of the Elderly, Taunton and Somerset NHS Trust, Taunton, United Kingdom

P469 EFFECT OF STATINS ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN

K. Stefikova*¹, V. Spustova¹, Z. Krivosikova¹, R. Dzurik¹

¹Department of Clinical and Experimental Pharmacotherapy, Slovak Medical University, Bratislava, Slovakia

P470 CONSISTENT EFFICACY WITH INTERMITTENT INTRAVENOUS IBANDRONATE INJECTIONS IN POSTMENOPAUSAL OSTEOPOROSIS: DIVA 2-YEAR ANALYSIS

J. J. Stepan*¹, G. Bianchi², E. Czerwinski³, C. Hughes⁴, N. Mairon⁴, D. Masanauskaitė⁴, J. A. Stakkestad⁵

¹ Charles University, Prague, Czech Republic, ² Ospedale La Colletta, Azienda Sanitaria Genovese, Genova, Italy, ³ Krakow Medical Centre, Krakow, Poland, ⁴ F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵ CECOR AS, Haugesund, Norway

P471 ONCE-MONTHLY IBANDRONATE DOSING IS MORE EFFECTIVE THAN DAILY DOSING FOR IMPROVING BONE MINERAL DENSITY: MOBILE 2-YEAR ANALYSIS

M. Stone*¹, J. Hensen², J. A. Stakkestad³, C. Hughes⁴, N. Mairon⁴, K. Coutant⁴, C. Christiansen⁵

¹ Llandough Hospital, Cardiff, United Kingdom, ² Klinikum Hannover Nordstadt, Hannover, Germany, ³ CECOR AS, Haugesund, Norway, ⁴ F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵ Center for Basic and Clinical Research, Ballerup Byvej, Denmark

P472 ESTIMATING STRUCTURAL PROPERTIES OF TRABECULAR BONE FROM GRAY-LEVEL LOW-RESOLUTION IMAGES

Z. Tabor*¹, E. Rokita¹, P. Gluszko²

¹Department of Biophysics, ²Department of Rheumatology, Collegium Medicum Jagiellonian University, Cracow, Poland

P473 DETERMINING OPTIMAL CUT OF TRABECULAR BONE

Z. Tabor*¹

¹Department of Biophysics, Collegium Medicum Jagiellonian University, Cracow, Poland

P474 URINARY OSTEOCALCIN AND OTHER MARKERS OF BONE METABOLISM: EFFECT OF RISEDRONATE THERAPY

A. Tamm*¹, J. Kumm¹, K. Rohtla¹, K. K. Ivaska²

¹Laboratory Medicine, University of Tartu, Tartu, Estonia, ²Institute of Clinical Sciences, University of Lund, Malmö, Sweden

P475 A MONTHLY DOSING REGIMEN OF RISEDRONATE REDUCES BONE TURNOVER SIMILAR TO DAILY ADMINISTRATION

G. A. Thompson*¹, D. J. Schnell¹, D. A. Russell¹, D. E. Burgio¹, L. A. Sun¹

¹Drug Development, Procter and Gamble Pharmaceuticals, Mason, United States

P476 RISEDRONATE PHARMACOKINETICS FOLLOWING DAILY AND MONTHLY DOSING REGIMENS

G. A. Thompson*¹, D. A. Russell¹, D. J. Schnell¹, D. E. Burgio¹, L. A. Sun¹

¹Drug Development, Procter and Gamble Pharmaceuticals, Mason, United States

P477 RISEDRONATE 5 MG DAILY FOR TWO YEARS PREVENTS BONE LOSS IN LATE POSTMENOPAUSAL WOMEN WITH OSTEOPENIA

M. Välimäki*¹, H. Kröger², J. Farrerons Minguella³, T. Boermans⁴, J. I. Halse⁵, M. Sääf⁶

¹Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, Helsinki, ²Department of Surgery and Orthopaedics, Kuopio University Hospital, Kuopio, Finland, ³Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Lutterstraat 2a, 7581 BV, Losser, Netherlands, ⁵Osteoporosis Clinic, Specialist Centre Pilestredet Park, Oslo, Norway, ⁶Dept of Endocrinology, Metabolism and Diabetology, Karolinska University Hospital Solna, Stockholm, Sweden

P478 PROPHYLACTIC SODIUM FLUORIDE PREVENTS OSTEOPOROSIS IN OSTEOPENIC PATIENTS

D. H. Van Papendorp*¹, A. M. Koorts¹

¹Physiology, University of Pretoria, Pretoria, South Africa

P479 EFFICACY OF GASTROINTESTINALLY APPLIED BMP-6 IN NEWBORN AND AGED OVARIECTOMIZED RATS

P. Simic*¹, B. Macek¹, H. Oppermann¹, S. Vukicevic¹

¹Department of Anatomy, School of Medicine, Zagreb, Croatia

P480 IMPROVED PATIENT EDUCATION AND SUPPORT MAY ENHANCE ADHERENCE TO BISPHOSPHONATE THERAPY

M. A. Koay¹, **M. Walker***¹, A. Corner¹, F. Hammond², A. Carr²

¹Medical Department, Roche Products Ltd, Welwyn Garden City, ²Clinimatrix, United Kingdom

P481 ALENDRONATE IMPROVES THE STRUCTURAL GEOMETRY OF THE PROXIMAL FEMUR IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN

T. J. Beck*¹, J. A. Cauley², A. E. De Papp³, L. E. Wehren⁴, D. T. Baran⁵

¹Johns Hopkins Medical Institutions, Baltimore, MD, ²University of Pittsburgh, Pittsburgh, PA,

³Merck Research Laboratories, Horsham, PA, ⁴Medical Communications, Merck Research

Laboratories, Rahway, NJ, ⁵Merck Research Laboratories, Upper Gwynedd, PA, United States

P482 EFFECT OF ONCE-WEEKLY ALENDRONATE 70 MG AND VITAMIN D3 2800 IU ON FRACTIONAL CALCIUM ABSORPTION IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN: A 4-WEEK, DOUBLE-BLIND, RANDOMIZED, CONTROLLED MULTI-CENTER CLINICAL TRIAL

R. Robson*¹, D. Kendler², M. Handel³, S. Shapses⁴, Z. Yang⁵, T. Wilson⁵, M. Liu⁵, A. Mantz⁵, L. E. Wehren⁶, A. Santora⁵

¹Christchurch Clinical Trials, Christchurch, New Zealand, ²Osteoporosis Research Centre, Vancouver,

BC, Canada, ³Prince of Wales Hospital, Randwick, NSW, Australia, ⁴Rutgers University, New

Brunswick, NJ, ⁵Medical Communications, Merck Research Laboratories, Rahway, NJ, United States

P483 METHODOLOGY FOR DETERMINATION OF FRACTIONAL CALCIUM ABSORPTION

R. Sherrell*¹, P. Field¹, S. Shapses¹, R. Robson², M. Liu³, W. Bayne³, E. Woolf³, L. E. Wehren⁴, A. Santora³

¹Rutgers University, New Brunswick, NJ, United States, ²Christchurch Clinical Trials, Christchurch,

New Zealand, ³Medical Communications, Merck Research Laboratories, Rahway, NJ, United States

P484 WEEK-BY-WEEK EFFECTS OF MONTHLY IBANDRONATE ON BIOCHEMICAL MARKERS OF BONE RESORPTION: RESULTS OF A 3-MONTH RANDOMIZED TRIAL

P. Geusens*¹, J. Walliser², R. Rovayo³, A. W. C. Kung⁴, N. Verbruggen⁵, M. Shivaprakash⁶, L. E.

Wehren⁷, M. E. Melton⁶

¹Universitaire Campus Gebouw C, Diepenbeek, Belgium, ²Hospital Angeles del Pedregal, Padierna,

Mexico, ³Central University of Ecuador, Eloy Alfaro, Ecuador, ⁴Queen Mary Hospital, Hong Kong,

China, ⁵Merck Research Laboratories, Brussels, Belgium, ⁶Merck Research Laboratories, Whitehouse

Station, NJ, ⁷Medical Communications, Merck Research Laboratories, Rahway, NJ, United States

P485 REVIEW OF ALENDRONATE EFFECTS ON HISTOMORPHOMETRIC PARAMETERS: NO EVIDENCE FOR OVER-SUPPRESSION OF TURNOVER

R. R. Recker*¹, L. E. Wehren², D. B. Kimmel³

¹Osteoporosis Research Center, Creighton University, Omaha, NB, ²Medical Communications, Merck

Research Laboratories, Rahway, NJ, ³Merck Research Laboratories, West Point, PA, United States

P486 THRESHOLD RESPONSE OF SERUM CTX TO MONTHLY ORAL IBANDRONATE THROUGHOUT DOSING INTERVAL: RESULTS OF A 3-MONTH RANDOMIZED TRIAL

P. Geusens*¹, J. Walliser², R. Rovayo³, A. W. C. Kung⁴, M. Shivaprakash⁵, N. Verbruggen⁶, L. E.

Wehren⁷, M. E. Melton⁵

¹Universitaire Campus Gebouw C, Diepenbeek, Belgium, ²Hospital Angeles del Pedregal, Padierna,

Mexico, ³Central University of Ecuador, Eloy Alfaro, Ecuador, ⁴Queen Mary Hospital, Hong Kong,

China, ⁵ Merck Research Laboratories, Whitehouse Station, NJ, United States, ⁶ Merck Research Laboratories, Brussels, Belgium, ⁷ Medical Communications, Merck Research Laboratories, Rahway, NJ, United States

P487 CONSTRUCTION AND MATERIAL PROPERTIES OF THE BONE

J. Wendlova*¹

¹Osteological unit, University Hospital and Policlinic, Bratislava, Slovakia

P488 BONE DISTRIBUTION IN THE CROSS SECTIONS THROUGHOUT THE FEMORAL NECK AND INTERTROCHANTERIC REGIONS: A STUDY USING CLINICAL QCT

I. Maric*¹, R. Eastell², L. Yang²

¹Department of Anatomy, University of Rijeka, Rijeka, Croatia, ²Division of Clinical Sciences, University of Sheffield, Sheffield, United Kingdom

P489 A DXA-BASED COMPOSITE BEAM MODEL OF THE PROXIMAL FEMUR FOR STRESS ESTIMATION

L. Yang*¹, E. V. McCloskey¹, R. Eastell¹

¹Division of Clinical Sciences, University of Sheffield, Sheffield, United Kingdom

P490 BALLOON KYPHOPLASTY FOR OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES - LONDON EXPERIENCE

J. S. Yeh*¹, S. Karanth¹, H. Ellamushi¹, C. Thakkar², F. Afshar¹

¹Neurosurgery, ²Neuroradiology, Barts and The London NHS Trust, London, United Kingdom